Blog

Fred Hutch researchers engineer complex immunotherapy that may target relapsing leukemia – EurekAlert (press release)


EurekAlert (press release)

Fred Hutch researchers engineer complex immunotherapy that may target relapsing leukemia
EurekAlert (press release)
The findings, published online in the journal Blood, provide the basis for launching a first-in-human clinical trial of this new immunotherapy, which relies on engineered T-cell receptors, or TCRs. This immunotherapy represents a different method of

and more »

2017-10-25 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.